QIAGEN N.V.

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers...

QIAGEN collaborates with McGill University to advance microbiome research

QIAGEN and McGill University to collaborate on microbiome research projects to generate evidence-based knowledge for medicine and public health McGill will serve as a beta-testing site for new QIAGEN microbiome solutions Partnership strengthens...

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of...

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed...

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment

QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can...

QIAGEN Digital Insights launches PGXI knowledgebase to enable access to expert-curated pharmacogenomic insights

New knowledgebase with expert-curated pharmacogenomic content on how genetic variations influence drug response Centralized data and automated annotation enable scientific and translational researchers to rapidly generate genomic and drug...

QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications

Portfolio expansion reinforces QIAGEN’s leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 instruments designed to enhance...

QIAGEN N.V. to release results for Q3 2024 and hold webcast

Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, November 6 , shortly...

QIAGEN Digital Insights Expands Biopharma Collaboration with Neo4j to advance Biomedical Data Analysis

Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer